Levetiracetam (Keppra) for Dogs

A plain-English guide to canine levetiracetam therapy. Dose, side effects, the honeymoon effect, and the way phenobarbital changes everything about the dose math. Every claim below is anchored to the ACVIM 2015 Consensus, the IVETF 2015 Consensus, or peer-reviewed JVIM pharmacokinetic studies. Your veterinarian's prescription always takes priority.

What levetiracetam is, and where it fits

Levetiracetam works on a presynaptic vesicle protein called SV2A, modulating how neurotransmitters are released [2]. That is a completely different mechanism from phenobarbital, which works on GABA-A receptors, and from potassium bromide. Different mechanism, complementary effects: that is why levetiracetam is added on top of phenobarbital rather than replacing it.

Both consensus statements are explicit. Levetiracetam is not first-line for canine idiopathic epilepsy. The ACVIM 2015 Consensus notes that no controlled studies have evaluated levetiracetam as first-line in dogs, and all the controlled evidence is for adjunctive use [1]. IVETF 2015 grades the evidence as "fair" for use as an add-on [2].

Where levetiracetam is preferred over phenobarbital:

• Dogs with known or suspected liver disease (since LEV is barely metabolized hepatically) [1, 2].
• Dogs with cluster seizures, where the pulse protocol gives short-term high-dose coverage [2, 5].
• Dogs whose phenobarbital is at the top of the therapeutic range (around 35 mcg/mL) without adequate seizure control [1].

Dose: IR versus XR

IVETF cites a range of TID to QID (three to four times daily) for IR [2]. Many veterinary neurologists move dogs to QID when they are also on phenobarbital because of the clearance induction described below.

The phenobarbital interaction (the most important section)

This is the single most clinically important thing to know about combining levetiracetam with another antiseizure drug. Phenobarbital is a potent inducer of liver enzymes (cytochrome P450), and that induction substantially increases the clearance of levetiracetam.

The numbers from Munana et al., JVIM 2018, in epileptic dogs on LEV-XR with and without phenobarbital [4]:

• Peak concentration (Cmax) dropped from 33.0 mcg/mL on LEV-XR alone to 13.4 mcg/mL on LEV-XR with phenobarbital. That is roughly a 60 percent reduction.
• Clearance rose from 0.08 to 0.17 L/kg/hour, more than doubling.
• Three of 6 dogs on concurrent phenobarbital fell below 5 mcg/mL at two sampling points, well below the human-extrapolated therapeutic range.

What that means in practice: a dog on LEV-XR plus phenobarbital is often getting half the levetiracetam exposure that the dose math implies. IVETF says the levetiracetam dose may need to be increased, or the dosing interval shortened, when combined with phenobarbital [2]. ACVIM specifically recommends therapeutic drug monitoring when the two are combined [1].

Zonisamide does not clinically alter levetiracetam pharmacokinetics, so the same caution does not apply when those two are combined [4].

The honeymoon effect

The "honeymoon effect" is a documented loss of efficacy after a few months of consistent dosing. ACVIM 2015 cites this from the Volk and Munana series: 6 of 9 (67 percent) responders had an increase in seizure frequency and seizure days per month after 4 to 8 months of continued treatment at the last effective levetiracetam dose [1]. IVETF lists the phenomenon explicitly: "Some dogs develop a tolerance to levetiracetam when used chronically. This phenomenon, the honeymoon effect, has been documented for other AEDs, e.g. zonisamide and levetiracetam in dogs with epilepsy" [2].

The clinical implication: if your dog responded well at the start and is now having more seizures despite no dose change, the loss may be drug-specific, not a sign of progressing disease. That is a conversation with your veterinary neurologist.

Side effects: maintenance vs pulse

From Packer et al., BMC Veterinary Research 2015, in a cohort of 52 dogs with idiopathic epilepsy [5]:

Pulse therapy is harsher in the short term and easier on the dog over the long term (no daily medication), but each pulse course produces roughly triple the side-effect rate of steady maintenance dosing [5]. No dog in the cited cohort experienced life-threatening side effects.

The ACVIM-listed Type I (predictable, dose-dependent) side effects are sedation, ataxia, restlessness, vomiting, and decreased appetite. Ataxia was the only effect that differed significantly from baseline in the controlled data [1].

Behavioral changes (often under-reported)

Erath et al., Frontiers in Veterinary Science 2020, surveyed owners of 84 levetiracetam-treated dogs [6]:

• 51 percent showed some behavioral change.
• 16.7 percent showed negative behavioral changes.
• 11 percent showed aggression.
• 5 percent showed hyperactivity.
• Onset typically within the first 2 weeks (p less than 0.0001).

This is not in the consensus guidelines because it is recent. If your dog seems behaviorally off in the first 2 weeks of starting levetiracetam, the drug is a likely cause.

Hepatic and renal safety

Levetiracetam is barely metabolized by the liver, has minimal protein binding, and is excreted primarily unchanged in the urine [1, 2]. This is exactly why it is the preferred drug when phenobarbital is contraindicated by liver disease.

The renal caveat: clearance is reduced in dogs with significant renal impairment, so the dose must be reduced [2]. For dogs with CKD, geriatric dogs, or dogs on nephrotoxic medications, dose adjustment is on the table.

Therapeutic drug monitoring

There is no published canine therapeutic range for levetiracetam. Both consensuses extrapolate the human range of 12 to 46 mcg/mL as a rough guide [1, 2].

ACVIM says routine monitoring is not necessary due to the wide therapeutic index, except when levetiracetam is combined with phenobarbital. In that case, monitoring is specifically recommended because of clearance induction [1]. Recommended sampling: 3 hours post-dose peak and pre-dose trough [3].

Pulse protocol for cluster seizures

The IVETF pulse protocol is the published gold standard for cluster seizure prevention in epileptic dogs [2]:

1. Initial dose: 60 mg/kg by mouth or parenterally, given after a seizure occurs or when pre-ictal signs are recognized by the owner.
2. Follow-up: 20 mg/kg every 8 hours until no seizures have occurred for 48 hours.
3. Then stop, return to baseline maintenance ASMs (typically phenobarbital).

The Packer 2015 real-world cohort showed pulse therapy achieved 69 percent responders (50 percent or greater seizure reduction) and 15 percent seizure-free, with no statistical efficacy difference from steady maintenance [5]. The tradeoff is the side-effect burden during pulses.

The 2024 ACVIM Consensus on Status Epilepticus and Cluster Seizures grades the routes [7]:

• Oral pulse levetiracetam in dogs: Recommendation B.
• Rectal levetiracetam: Recommendation B.
• Intramuscular levetiracetam: Recommendation C.
• Intravenous levetiracetam in hospital: Recommendation A (the highest).

Does XR really cover q12h in dogs?

The honest answer: it depends on the dog and whether they are on phenobarbital.

• Healthy dogs, single dose 30 mg/kg XR: serum stays above 5 mcg/mL for about 20 hours [3]. q12h covers comfortably.
• Epileptic dogs on chronic XR 23.5 to 31.9 mg/kg q12h: 59 percent (10 of 17) fell below 10 mcg/mL at some sampling point [4]. Trough fluctuation is 50 to 80 percent across the dosing interval.
• Epileptic dogs on XR plus phenobarbital: 3 of 6 fell below 5 mcg/mL at two timepoints [4]. q12h is often inadequate in this combination.

Practical translation: if your dog is on LEV-XR alone and seizures are controlled, q12h likely works. If you add phenobarbital, talk to your vet about shifting to LEV-IR three times daily, or adjusting the LEV-XR interval to every 8 hours.

Missed dose and discontinuation

Neither ACVIM nor IVETF publishes a levetiracetam-specific missed-dose protocol. The short half-life in dogs (around 3 to 4 hours for IR, around 5 hours for XR) means a single missed dose drops the trough below the human reference range quickly [3]. Clinical convention: give the next scheduled dose without doubling.

For discontinuation: the general antiseizure withdrawal rule applies. A dog should be seizure-free for at least 1 to 2 years before tapering, and the dose should be reduced by 20 percent or less per month to avoid withdrawal seizures [2]. Abrupt stopping is contraindicated.

Tracking levetiracetam at home so the dose math stays honest

Levetiracetam is the most timing-sensitive of the common canine antiseizure drugs. The IR formulation needs every 8 hours, which is an unforgiving schedule for owners. Combined with phenobarbital's clearance induction and the honeymoon effect, small adherence drift produces large clinical effects.

Remewdy is a free iPhone app that logs each dose in one tap, sends reminders at the times you set, and records seizure events with type, duration, and post-seizure notes. The compliance heat map shows the last 4 to 12 weeks at a glance. Premium users print a PDF for the vet that combines dose history, seizure events, weight, and notes from the same window.

The app does not prescribe, change doses, or interpret bloodwork. It does the boring part: keeping the record straight so your vet can do the medical part well.